全球CTEPH注册研究:PEA、BPA与药物治疗的长期结局
该全球注册研究纳入20国34中心1009例新诊断CTEPH患者,随访至2019年。60%行PEA,18%行BPA,余未行机械干预者76%用肺动脉高压药物。三组3年生存率分别为94%、92%、71%,PEA组较前注册期提高5%,抗凝方案类型不影响生存。
要点
- PEA和BPA组3年生存率分别为94%和92%,未行机械干预组为71%。
- PEA组3年生存率较2007-2012年注册期提高5%。
- 维生素K拮抗剂与非维生素K口服抗凝药之间生存无差异(P=0.756)。
核心结论
- 自BPA和获批肺动脉高压药物引入以来,CTEPH患者生存率显著改善。
- 抗凝方案类型(维生素K拮抗剂 vs 非维生素K口服抗凝药)不影响生存。
研究设计与样本
- 国际多中心注册研究,纳入20国34中心1009例新诊断连续CTEPH患者。
- 入组时间2015年2月至2016年9月,随访至2019年9月,观察期>3年且≤5.6年。
主要发现
- 605例(60%)行PEA,185例(18%)行BPA;剩余219例未行机械干预者中76%接受肺动脉高压药物治疗。
- PEA组和BPA组中分别有38%和78%同时接受肺动脉高压药物治疗。
- 诊断时中位年龄:BPA组66岁、无PEA/BPA组69岁,均高于PEA组的60岁。
- 所有组肺血管阻力(PVR)相似,平均643 dynes.s.cm-5。
- 观察期间死亡:PEA组7%、BPA组11%、未行机械干预组27%(P<0.001);3年生存率分别为94%、92%、71%。
关键数值与推荐
- Cox回归中,全球队列死亡风险降低与PEA和BPA相关。
- PEA组死亡风险降低与静脉血栓栓塞史和较低PVR相关。
- BPA组死亡风险降低与较低右心房压力相关。
- 未行机械干预组死亡风险降低与使用肺动脉高压药物、氧疗、较低右心房压力及功能分级相关。
临床怎么用
- 对于新诊断CTEPH患者,应评估PEA或BPA适应证,机械干预与药物治疗可联合使用。
- 抗凝治疗中维生素K拮抗剂与非维生素K口服抗凝药的选择可不以生存获益为决策依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The European Chronic Thromboembolic Pulmonary Hypertension (CTEPH) registry, conducted between 2007 and 2012, reported the major impact of pulmonary endarterectomy (PEA) on the long-term survival of patients with CTEPH. Since then, 2 additional treatments for inoperable CTEPH have become available: balloon pulmonary angioplasty (BPA), and an approved oral drug therapy with the guanylate cyclase stimulator riociguat. The current registry aimed to evaluate the effect of these new therapeutic approaches in a worldwide context. METHODS: Participation in this international global registry included 34 centers in 20 countries. Between February 2015 and September 2016, 1009 newly diagnosed, consecutive patients were included and followed until September 2019. RESULTS: Overall, 605 patients (60%) underwent PEA and 185 (18%) underwent BPA; 76% of the 219 remaining patients not receiving mechanical intervention (ie, neither PEA nor BPA) were treated with pulmonary hypertension drugs. Of patients undergoing PEA and BPA, 38% and 78% also received drugs for pulmonary hypertension, respectively. Median age at diagnosis was higher in the BPA and No PEA/BPA groups than in the PEA group: 66 and 69, respectively, versus 60 years. Pulmonary vascular resistance (PVR) was similar in all groups, with an average of 643 dynes.s.cm-5. During the observation period (>3 years; ≤5.6 years), death was reported in 7%, 11%, and 27% of patients treated by PEA and BPA, and those receiving no mechanical intervention (P<0.001). In Kaplan-Meier analysis, 3-year survival was 94%, 92%, and 71% in the 3 groups, respectively. PEA 3-year survival improved by 5% from that observed between 2007 and 2012. There was no survival difference in patients receiving vitamin K antagonists and non-vitamin K oral anticoagulants (P=0.756). In Cox regression, reduced mortality was associated with: PEA and BPA in the global cohort; history of venous thromboembolism and lower PVR in the PEA group; lower right atrial pressure in the BPA group; and use of pulmonary hypertension drugs, oxygen therapy, and lower right atrial pressure, as well as functional class in the group receiving no mechanical intervention. CONCLUSIONS: This second international CTEPH registry reveals important improvement in patient survival since the introduction of BPA and an approved drug for pulmonary hypertension. The type of anticoagulation regimen did not influence survival. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02656238.
引用
- Delcroix M, Pepke-Zaba J, D'Armini AM, et al. Worldwide CTEPH Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy. Circulation. 2024. PMID: 39286890. doi:10.1161/CIRCULATIONAHA.124.068610
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。